Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BMS 833923

Next Previous
Drug Profile

BMS 833923

Alternative Names: BMS-833923; XL-139

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Exelixis
  • Developer Bristol-Myers Squibb; Exelixis
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Hedgehog cell signalling pathway inhibitors; SMO protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Gastrointestinal cancer; Multiple myeloma; Small cell lung cancer; Solid tumours
  • Discontinued Chronic myeloid leukaemia

Most Recent Events

  • 15 Sep 2020 Discontinued - Phase-I/II for Chronic myeloid leukaemia (Combination therapy, Second-line therapy or greater) in United Kingdom, Italy, Germany, Finland, Canada, USA, France (PO) before September 2020
  • 15 Sep 2020 Discontinued - Phase-II for Chronic myeloid leukaemia (Combination therapy, First-line therapy, Newly diagnosed) in Germany, Canada, USA, Spain, Poland, Finland, Belgium, Argentina, France (PO) before September 2020
  • 01 Jan 2017 Bristol-Myers Squibb terminates a phase II trial as no participants enrolled in this trial could receive the recommended phase 2 dose in Chronic myeloid leukaemia (Newly diagnosed, First-line therapy, Combination therapy) in USA, Argentina, Belgium, Canada, Finland, France, Germany, Poland and Spain (NCT01357655)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top